150 related articles for article (PubMed ID: 36034941)
1. Prognostic Value of MUC16 Mutation and Its Correlation with Immunity in Hepatocellular Carcinoma Patients.
Liu B; Dong Z; Lu Y; Ma J; Ma Z; Wang H
Evid Based Complement Alternat Med; 2022; 2022():3478861. PubMed ID: 36034941
[TBL] [Abstract][Full Text] [Related]
2. Bioinformatic Analysis of Immune Significance of RYR2 Mutation in Breast Cancer.
Xu Z; Xiang L; Wang R; Xiong Y; Zhou H; Gu H; Wang J; Peng L
Biomed Res Int; 2021; 2021():8072796. PubMed ID: 34888385
[TBL] [Abstract][Full Text] [Related]
3. CSMD3 is Associated with Tumor Mutation Burden and Immune Infiltration in Ovarian Cancer Patients.
Lu N; Liu J; Xu M; Liang J; Wang Y; Wu Z; Xing Y; Diao F
Int J Gen Med; 2021; 14():7647-7657. PubMed ID: 34764678
[TBL] [Abstract][Full Text] [Related]
4.
Xie X; Tang Y; Sheng J; Shu P; Zhu X; Cai X; Zhao C; Wang L; Huang X
Front Cell Dev Biol; 2021; 9():761758. PubMed ID: 34746153
[TBL] [Abstract][Full Text] [Related]
5. Mucin 4 mutation is associated with tumor mutation burden and promotes antitumor immunity in colon cancer patients.
Peng L; Li Y; Gu H; Xiang L; Xiong Y; Wang R; Zhou H; Wang J
Aging (Albany NY); 2021 Mar; 13(6):9043-9055. PubMed ID: 33714943
[TBL] [Abstract][Full Text] [Related]
6. Co-mutation of TP53 and TTN is Correlated with the Efficacy of Immunotherapy in Lung Squamous Cell Carcinoma.
Ying K; Zou L; Wang D; Wang R; Qian J
Comb Chem High Throughput Screen; 2023 Oct; ():. PubMed ID: 37904553
[TBL] [Abstract][Full Text] [Related]
7. FLG Gene Mutation Up-regulates the Abnormal Tumor Immune Response and Promotes the Progression of Prostate Cancer.
Zhang P; An Z; Sun C; Xu Y; Zhang Z
Curr Pharm Biotechnol; 2022; 23(14):1658-1670. PubMed ID: 35422210
[TBL] [Abstract][Full Text] [Related]
8. Mutation of MUC16 Is Associated With Tumor Mutational Burden and Lymph Node Metastasis in Patients With Gastric Cancer.
Zhang F; Li X; Chen H; Guo J; Xiong Z; Yin S; Jin L; Chen X; Luo D; Tang H; Mao C; Lian L
Front Med (Lausanne); 2022; 9():836892. PubMed ID: 35211490
[TBL] [Abstract][Full Text] [Related]
9. Correlation analysis of tumor mutation burden of hepatocellular carcinoma based on data mining.
Zhou W; Fang D; He Y; Wei J
J Gastrointest Oncol; 2021 Jun; 12(3):1117-1131. PubMed ID: 34295561
[TBL] [Abstract][Full Text] [Related]
10. FAT3 Mutation Is Associated With Tumor Mutation Burden and Poor Prognosis in Esophageal Cancer.
Guo Z; Yan X; Song C; Wang Q; Wang Y; Liu XP; Huang J; Li S; Hu W
Front Oncol; 2021; 11():603660. PubMed ID: 33816234
[TBL] [Abstract][Full Text] [Related]
11. Mutations in the
Zou S; Ye J; Hu S; Wei Y; Xu J
Int J Gen Med; 2022; 15():19-31. PubMed ID: 35018111
[TBL] [Abstract][Full Text] [Related]
12. LRP1B is a Potential Biomarker for Tumor Immunogenicity and Prognosis of HCC Patients Receiving ICI Treatment.
Cheng Y; Tang R; Li X; Wang B; Cheng Y; Xiao S; Sun P; Yu W; Li C; Lin X; Zhu Y
J Hepatocell Carcinoma; 2022; 9():203-220. PubMed ID: 35345553
[TBL] [Abstract][Full Text] [Related]
13. Effect of
Wang Z; Hou H; Zhang H; Duan X; Li L; Meng L
Am J Transl Res; 2022; 14(2):849-862. PubMed ID: 35273689
[TBL] [Abstract][Full Text] [Related]
14.
Sun Y; Li L; Yao W; Liu X; Yang Y; Ma B; Xue D
Front Genet; 2021; 12():762160. PubMed ID: 34795697
[TBL] [Abstract][Full Text] [Related]
15. EP300 mutation is associated with tumor mutation burden and promotes antitumor immunity in bladder cancer patients.
Zhu G; Pei L; Li Y; Gou X
Aging (Albany NY); 2020 Feb; 12(3):2132-2141. PubMed ID: 32012118
[TBL] [Abstract][Full Text] [Related]
16. Establishment of a Necroptosis-Related Prognostic Signature to Reveal Immune Infiltration and Predict Drug Sensitivity in Hepatocellular Carcinoma.
Ren H; Zheng J; Cheng Q; Yang X; Fu Q
Front Genet; 2022; 13():900713. PubMed ID: 35957699
[No Abstract] [Full Text] [Related]
17. Association of MUC16 Mutation With Tumor Mutation Load and Outcomes in Patients With Gastric Cancer.
Li X; Pasche B; Zhang W; Chen K
JAMA Oncol; 2018 Dec; 4(12):1691-1698. PubMed ID: 30098163
[TBL] [Abstract][Full Text] [Related]
18. Mutational and transcriptional alterations and clinicopathological factors predict the prognosis of stage I hepatocellular carcinoma : Prediction of stage I HCC prognosis.
Li Z; Gao H; Zhang X; Liu Q; Chen G
BMC Gastroenterol; 2022 Sep; 22(1):427. PubMed ID: 36153509
[TBL] [Abstract][Full Text] [Related]
19. Prognostic analysis of tumor mutation burden and immune infiltration in hepatocellular carcinoma based on TCGA data.
Liu S; Tang Q; Huang J; Zhan M; Zhao W; Yang X; Li Y; Qiu L; Zhang F; Lu L; He X
Aging (Albany NY); 2021 Apr; 13(8):11257-11280. PubMed ID: 33820866
[TBL] [Abstract][Full Text] [Related]
20. The Mutation and Expression Level of LRP1B are Associated with Immune Infiltration and Prognosis in Hepatocellular Carcinoma.
Wang M; Xiong Z
Int J Gen Med; 2021; 14():6343-6358. PubMed ID: 34629898
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
